IOncology

In the stage of metastatic hormone-sensitive prostate cancer (mHSPC), effective treatment is crucial to delaying the progression to castration-resistant stages (mCRPC), thereby extending patient survival. From August 8-11, 2024, the Annual Meeting of the Urological Surgeon Branch of the Chinese Medical Doctor Association (CUDA) was grandly held in Xi'an, Shaanxi Province. At the conference, Dr. Kan Gong from Peking University First Hospital delivered a comprehensive presentation on the "Clinical Value of Novel Endocrine System Therapies in mHSPC." Following the event,Urology Frontier invited Professor Gong to further discuss the clinical needs of mHSPC patients, novel endocrine treatment strategies, and the exploratory research conducted by his team.

In 1974, David T. Carr, Oleg S. Selawry, Lawrence Broder, Clifton Mountain, and George Higgins recruited over 250 founding members from around the world and organized the first meeting of the International Association for the Study of Lung Cancer (IASLC) in Florence, Italy. Fifty years later, the field of lung cancer has seen countless scientific advancements. Conference Chairs Sandip Patel, Linda Martin, Narjust Florez, and Fabio Ynoe de Moraes have developed the educational agenda for the 2024 World Conference on Lung Cancer (WCLC), which will not only highlight the latest scientific discoveries in thoracic oncology but also celebrate the historic progress achieved by IASLC over the past five decades.

Kidney cancer is one of the three most common urological tumors in China, with an increasing incidence rate in recent years. As surgical techniques and new treatment strategies for kidney cancer have advanced, patient survival rates have also improved. At the 2024 Annual Meeting of the Urological Surgeon Branch of the Chinese Medical Doctor Association (CUDA) in Xi'an, Oncology Frontier - Urology NewsUrology Frontier invited Professor He ZhisongDr. Zhisong He from Peking University First Hospital to share insights on the development of kidney cancer surgery in China, second-line treatments for advanced kidney cancer, and progress in the national kidney cancer quality control project.

Non-muscle-invasive bladder cancer (NMIBC) accounts for over 70% of all bladder cancer cases. For NMIBC patients, the primary treatment goals are to eliminate tumor cells, prevent recurrence and progression, while preserving bladder function and quality of life as much as possible. From August 8-11, 2024, the Annual Meeting of the Urological Surgeon Branch of the Chinese Medical Doctor Association (CUDA) was held in Xi'an. Following the event, Urology Frontier invited Dr. Hailong Hu from The Second Hospital of Tianjin Medical University to share insights on the unmet clinical needs of NMIBC patients in China, recent advances in novel treatment strategies, and future development directions.

In the rapidly evolving field of oncology, antibody-drug conjugates (ADCs) have emerged as one of the most promising advancements in targeted cancer therapy. The groundbreaking article titled "Spotlight on Ideal Target Antigens and Resistance in Antibody-Drug Conjugates: Strategies for Competitive Advancement," led by renowned oncologist Academician Binghe Xu, and co-authored by Dr. Mingxia Jiang and Dr. Qiao Li from the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, delves into the intricate world of ADCs. Published in the esteemed Drug Resistance Updates journal with an impact factor of 15.8, this article not only highlights the transformative potential of ADCs in precision oncology but also addresses the formidable challenge of drug resistance that threatens to undermine their efficacy.

In the rapidly evolving field of oncology, breakthroughs are continuously shaping the way we approach the most challenging cancers. One such breakthrough is the potential of Poly (Adenosine Diphosphate-Ribose) Polymerase inhibitors (PARPi) in the treatment of triple-negative breast cancer (TNBC), a particularly aggressive and hard-to-treat subtype of breast cancer. Academician Binghe Xu from the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College has authored a study published in Medicinal Research Reviews, a journal with an impact factor of 10.9. The study, titled “Poly (adenosine diphosphate-ribose) polymerase inhibitors in the treatment of triple-negative breast cancer with homologous recombination repair deficiency,” explores the potential of novel therapies known as PARP inhibitors. It specifically examines how these therapies can target the unique vulnerabilities of triple-negative breast cancer tumors with homolo

Breast cancer has now become the most common malignant tumor worldwide and is one of the most prevalent cancers among Chinese women, posing a serious threat to their physical and mental health. While significant progress has been made in the treatment and drug development for breast cancer, providing more targeted treatment options for different types of patients and improving survival rates and quality of life, our ultimate goal is to reduce the incidence of breast cancer through screening and prevention. Early detection is crucial for improving treatment outcomes and extending survival times. This article discusses breast cancer screening and how high-risk groups can reduce their risk of developing breast cancer.

After CDK4/6i treatment failure in HR+/HER2- breast cancer patients, do you lean more towards a PI3K inhibitor or an AKT inhibitor? At the Northern Salon of the 2024 Summer Breast Cancer Forum, during the "In-Depth Analysis" segment, Dr. Yuhua Song from The Affiliated Hospital of Qingdao University and Dr. Jing Yao from Union Hospital Affiliated with Huazhong University of Science and Technology each presented their views. Professor Song expressed a preference for PI3K inhibitors, while Professor Yao favored AKT inhibitors. Following the session, Cancer Outlook invited both experts to elaborate on their perspectives.

After the failure of TKI therapy in HER2-positive breast cancer, would you prefer an "ADC" or "HP+" regimen? At the Northern Salon of the 2024 Summer Breast Cancer Forum, during the "In-Depth Analysis" segment, Dr. Xuening Ji from Affiliated Zhongshan Hospital of Dalian University and Dr. Chunfang Hao from Tianjin Cancer Hospital shared their perspectives. Professor Ji advocated for the ADC approach, while Professor Hao supported the "HP+" regimen. Following the session Oncology frontier  invited both experts to elaborate on their viewpoints.

For many years, platinum-based chemotherapy has been the standard treatment for metastatic urothelial carcinoma. However, this year’s EV-302/KEYNOTE-A39 study results, published in the New England Journal of Medicine (NEJM), demonstrated that the combination of enfortumab vedotin and pembrolizumab (EV+P) significantly improves survival outcomes for patients with locally advanced or metastatic urothelial carcinoma. The 2024 ASCO Breakthrough conference, held from August 8-10 in Yokohama, Japan, presented the efficacy and patient-reported outcomes (PROs) from the KEYNOTE-A39 study. Here is a summary for our readers.